Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

1.0K
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
1.0K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.5K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.5K
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

2.7K
Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
2.7K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.5K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.5K
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

1.0K
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
1.0K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

697
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
697

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2018
Same author

Integrative Analysis of Dysregulated lncRNA-Associated ceRNA Network Reveals Functional lncRNAs in Gastric Cancer.

Genes·2018
Same author

Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression.

Oncogene·2018
Same author

Microbiota transplantation: concept, methodology and strategy for its modernization.

Protein & cell·2018
Same author

Nicotine induces aberrant hypermethylation of tumor suppressor genes in pancreatic epithelial ductal cells.

Biochemical and biophysical research communications·2018
Same author

Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.

Critical reviews in oncogenesis·2018

Related Experiment Video

Updated: Mar 1, 2026

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
10:31

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma

Published on: August 9, 2016

13.5K

Gastric adenocarcinoma.

Jaffer A Ajani1, Jeeyun Lee2, Takeshi Sano3

  • 1Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA.

Nature Reviews. Disease Primers
|June 2, 2017
PubMed
Summary

Gastric adenocarcinoma (GAC) presents a global health challenge, often diagnosed late due to limited screening. Early detection and Helicobacter pylori treatment offer potential primary prevention strategies for this heterogeneous cancer.

More Related Videos

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

1.8K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K

Related Experiment Videos

Last Updated: Mar 1, 2026

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
10:31

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma

Published on: August 9, 2016

13.5K
Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

1.8K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K

Area of Science:

  • Oncology
  • Gastroenterology
  • Infectious Disease

Background:

  • Gastric adenocarcinoma (GAC) represents a significant global health burden, with late diagnosis being common due to limited early detection strategies worldwide.
  • Helicobacter pylori infection is a key factor in many endemic GAC cases, suggesting that its eradication could be a viable primary prevention method.
  • GAC exhibits significant phenotypic and genotypic heterogeneity, impacting treatment approaches and patient outcomes.

Purpose of the Study:

  • To review the current landscape of gastric adenocarcinoma (GAC), including its epidemiology, risk factors, and treatment modalities.
  • To highlight the challenges in early detection and the potential of Helicobacter pylori eradication for primary prevention.
  • To discuss the promise of molecular and immune profiling in advancing GAC treatment, particularly with immune checkpoint inhibitors.

Main Methods:

  • Literature review of epidemiological data, risk factors, and treatment outcomes for GAC.
  • Analysis of the role of Helicobacter pylori in GAC development and prevention strategies.
  • Examination of recent advances in molecular and immune profiling of GAC and their therapeutic implications.

Main Results:

  • Early-stage GAC is treatable with endoscopic or surgical resection, while advanced stages (II-IV) require multidisciplinary approaches and have poor prognoses.
  • Advanced GAC (stage IV) has a median survival of approximately 9-10 months, underscoring the need for improved therapies.
  • Molecular and immune profiling are revealing GAC's heterogeneity and potential responsiveness to immune modulation, including immune checkpoint inhibitors.

Conclusions:

  • Despite challenges in early detection and treatment of advanced disease, ongoing molecular and immunological research offers hope for improved outcomes in gastric adenocarcinoma.
  • Targeting Helicobacter pylori infection presents a promising avenue for primary prevention of endemic GAC.
  • Further research into GAC's molecular characteristics and immune microenvironment is crucial for developing more effective therapeutic strategies and overcoming current survival limitations.